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INTRODUCTION
The incidence of breast cancer in Korea has been increas-
ing in recent years. Although this cancer is still much less
prevalent in Korea than in Europe and the United States, it
has been the most common cancer in Korean women since
2001 (1). Remarkably, the peak age of Korean women pre-
senting with breast cancer is in the 40’ s, a peak age 15-20
yr younger than in the United States. One of the character-
istics of hereditary breast cancer is a tendency towards younger
age at onset. Breast cancer is typically diagnosed at a young
age in Southeast Asia, including Korea, suggesting that genetic
factors may be important (2).
Although 20% to 25% of breast cancers are familial (i.e.,
associated with a family history of breast cancer), in Western
countries only 5% to 10% are hereditary, with an autosomal
dominant genetic determinant. Most hereditary breast cancers
are associated with mutations in the BRCA1 (MIN 113705)
and BRCA2 (MIN 600185) genes (3), which confer high sus-
ceptibility to familial breast and/or ovarian cancer (4, 5). Eth-
nicity plays a role in hereditary breast cancer through its asso-
ciation with particular “founder” mutations. For example, fou-
nder mutations have been identified in various ethnic groups,
including Icelanders, Ashkenazi Jews, Russians, and Israelis.
In Iceland, a single BRCA2 mutation (BRCA2 999del5) is
found in 24% of women diagnosed with breast cancer below
age 40 yr (6, 7). Twelve percent of unselected Jewish breast
cancer cases, including 28% of those diagnosed below age 50
yr, were found to carry 1 of 3 founder BRCA mutations (8).
In general, there is little data on the contribution of germline
BRCA mutations to breast cancer in Asia. Among unselected
breast cancer cases in the Philippines, the prevalence of BRCA
mutations was found to be 5.1% (2). Although nine germ-line
mutations were identified in 21 Korean families, including
two or more affected first- or second-degree relatives with
breast and/or ovarian cancer (9), knowledge of BRCA muta-
tions in the overall Korean breast cancer population is scanty.
To determine the prevalence of BRCA germline mutations
in Korean breast cancer patients, we performed mutational
analysis of the BRCA1 and BRCA2 genes in high-risk breast
cancer patients and in unselected patients using Conforma-
tion-Sensitive Gel Electrophoresis (CSGE).
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Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer
Patients
The incidence of breast cancer in Korea has been increasing in recent years, such
that it is now the most common female cancer. Breast cancer in Korea is charac-
terized by an earlier age of onset than in Western countries, suggesting that it would
be related with genetic background. We assayed germline mutations in the BRCA
genes to evaluate their genetic pathology in Korean breast cancer patients. The
study subjects consisted of 173 patients at clinically higher risk and 109 unselect-
ed patients. Germline mutations in the entire coding sequences of the BRCA1 and
BRCA2 genes were analyzed by Conformation-Sensitive Gel Electrophoresis
(CSGE), and any aberrantly-sized band was sequenced. BRCA mutations were
present in 12.7% of the high risk patients, compared with 2.8% of the unselected
patients. Among high risk patients, mutations were most prevalent in patients with
a family history of breast or first-degree ovarian cancer (22.1%), followed by those
with male breast cancer (20%), bilateral breast cancer (20%), multiple organ cancer
including breast (13%) and younger breast cancer patients (aged <35 yr) (8.1%).
Moreover, BRCA mutations were detected in 34.8% of patients having two high-
risk factors. These findings suggest that BRCA gene mutation analysis should be
performed on Korean patients with high-risk factors for breast cancer.
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MATERIALS AND METHODS
Subjects
The study subjects included 173 breast cancer patients at
higher risk of mutating BRCA genes at Asan Medical Cen-
ter, Seoul, between March 2002 and February 2003 and 109
unselected breast cancer patients treated at Korea University
Guro Hospital, Seoul, between January 2000 and December
2000. The high-risk patients included 86 with familial breast
or first-degree ovarian cancer histories, 74 with a younger age
at onset (<35 yr), 15 bilateral cancers, 5 male breast cancers,
and 16 multi-organ cancers (five thyroid cancers, three cer-
vical cancers, three stomach cancers, one ovarian cancer, one
skin cancer, and three unknown cancers), including breast
cancer. Of those with familial histories, seventy-one patients
had a history of breast cancer (50 in first-degree relatives in-
cluding 3 with a first-degree family history of ovarian cancer,
13 in second-degree relatives, and 8 in both first and second-
degree relatives including 1 with a first-degree family history
of ovarian cancer). Only 7 patients had first-degree ovarian
cancer histories, and the information on the rest 8 patients
was not available. The unselected patients were included ran-
domly without the information about their family histories
or other high-risk factors. Subjects were asked to fill out ques-
tionnaires to evaluate their personal and family histories, and
blood specimens were collected for determination of BRCA
mutations. Informed consent was obtained from all the sub-
jects in this study.
DNA purification from EDTA-blood
Genomic DNA was isolated from EDTA-blood using the
Accuprep DNA Purification kit (Bioneer, Korea).
Generation of polymerase chain reaction (PCR) products
BRCA1 and BRCA2 mutations were scanned as described
previously (12), with modifications. PCR products were syn-
thesized by amplification of 75 fragments overlapping the 22
coding exons of BRCA1 and the 26 coding exons of BRCA2.
PCR primers were designed to generate fragments of 220-
503 bp in length covering all coding exons and at least 40
bp of each exon-intron flanking region. In order to produce
75 fragments for both genes, 31 BRCA1 fragments were
generated in 9 triplexes and 2 duplexes, and 44 BRCA2 frag-
ments were generated in 11 triplexes, 4 duplexes, and 3 sin-
gles. For generation of fluorescent PCR products, each for-
ward primer was labeled at the 5′ end with one of the phos-
phoramidite dyes, HEX (yellow), TET (green), or 6-FAM
(blue), while the reverse primers were unlabeled. Primer
sequences and multiplex PCR conditions are available on
request (e-mail: dabb@labgenomics. com). Typically, PCR
reactions were performed in a reaction volume of 15  L con-
taining 1  L of DNA solution, 2.5 mM MgCl2, 1.25 mM
dNTP, 0.5  M of each primer and 1 U of TaKaRa Taq poly-
merase (TaKaRa Biomedicals, Japan). The amplification pro-
tocol consisted of denaturation at 95℃ for 10 min, followed
by 35 cycles of denaturation at 95℃ for 15 sec, annealing
at 57℃for 1 min, and extension at 72℃for 45 sec. To gen-
erate heteroduplexes, the samples were denatured at 95℃
for 5 min, annealed at 68℃ for 30 min and cooled at 4℃.
A 0.3-1.0  L aliquot of each PCR product was subsequently
used for F-CSGE analysis.
Fluorescent conformation-sensitive gel electrophoresis
(F-CSGE)
Samples were electrophoresed in 0.2 mm thick 12% poly-
acrylamide gels, containing a 99:1 ratio of acrylamide (BioRad,
CA, U.S.A.) to 1,2 bis-(acryolyl)piperazine (Fluka, Switzer-
land) and 15% (v/v) formamide, in 1×TBE buffer with a 36-
well comb. Samples were separated on a standard ABI 377
sequencer using 1×TBE. Each sample loading mixture con-
tained 0.3-1.0  L of multiplexed PCR product, 0.2  L size
standard labeled with TAMRA (GS500, Applied Biosystems,
CA, U.S.A.), 0.5  L dextran blue (50 mg/mL), and 0.5  L
freshly deionized formamide. 1-1.8  L aliquots of the samples
were applied per lane. Electrophoresis was performed at 2,000
V for 4.5 hr at 42℃in 1×TBE, and the data were analyzed
A B C D
T875 Homozygote (wild type)
TG AG A AGC GTGCA GCT G T GAG AAGC GC  GCAGC  TG TAA  T A A AA GCAA A C AG TAA T AA  A N NNA C A CN
T875 Heterozygote (SNP) (wild type) 1041 del AGC, insT (mutation)
Fig. 1. A typical scan of a F-CSGE fragment which harbors the BRCA1 sequence variations T875C (panel B) and 1041_1043delAGCinsT
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with GeneScan software (Applied Biosystems, CA, U.S.A.).
Sequencing of PCR products
Once a subset of PCR products with an aberrant CSGE pat-
tern had been identified, the PCR products were re-amplified
using the same primers as for CSGE and subjected to DNA
sequencing in both directions on an ABI3700 genetic analyzer
(Applied Biosystems) (Fig. 1).
Interpretation of sequence analysis results
The sequence analysis results were sorted into three catego-
ries. Positive for BRCA mutation included nonsense or frameshift
mutations that produce prematurely terminated (truncated)
protein products of BRCA1 or BRCA2, whose clinical sig-
nificance has been determined. Unverified mutations (UVs)
included missense mutations and mutations that occurred in
analyzed intronic regions whose clinical significance has not
yet been determined. Negative for BRCA mutation included
samples identical to a consensus wild-type sequence as well as
samples in which genetic variants of no substantial clinical
consequence were identified.
RESULTS
In 109 unselected breast cancer patients, 3 individuals (2.8
%) carried BRCA mutations, two in BRCA1 and one in
BRCA2; of these, one was a nonsense mutation and two were
frame shift mutations. In contrast, 22 of the 173 high-risk
breast cancer patients (12.7%) carried BRCA mutations, 15
(8.7%) in BRCA1 and seven (4%) in BRCA2; of these, seven
were nonsense mutations and 15 were frame shift mutations
(Fig. 2).
Among the 5 subsets of high risk patients, mutations were
most prevalent in patients having a family history of breast or
first-degree ovarian cancer (22.1%), followed by those with
male breast cancer (20%), bilateral breast cancer (20%), mul-
tiple organ cancer including breast cancer (13%) and younger
breast cancer patients (aged <35 yr) (8.1%) (Table 1).
We found that BRCA mutations were present in 8 of 23
patients (34.8%) with two high-risk factors. BRCA1 muta-
tions were detected in 3 of 14 patients (21.4%) with family
history and early-onset (<35 yr), one of 2 patients (50%) with
family history and bilateral cancer, one of 2 patients (50%)
with family history and male breast cancer, one of 2 patients
(50%) with family history and multi-organ cancer, one of 2
patients (50%) with early-onset and bilateral cancer, and none
of one patient with early-onset and multi-organ cancer. BRCA2
mutation was studied in 14 patients with family history and
early-onset (<35 yr) and detected in one of the 14 patients
(7.1%).
DISCUSSION
Mutations in the BRCA1 and BRCA2 genes in females con-
fer highly elevated risks of developing cancers of the breast and
ovary. Ever since the BRCA1 and BRCA2 genes were iden-
tified in 1994 and 1995, respectively, there has been contro-
versy over whether presymptomatic testing for these mutations
would be clinically beneficial, and, if so, who would be eligible
for testing (13). Since the prevalence of BRCA1 and BRCA2
mutations in most populations is low, many advisory bodies,
including one under the auspices of the American Society for
Clinical Oncology, have recommended that testing be restrict-
ed to women at high risk of developing breast or ovarian can-
Fig. 2. BRCA mutations in breast cancer patients with high-risk fac-
tors in Korea (n=173). *UV, unverified mutation.
BRCA mutation
UV*
No mutation
121
Nonsense: 7 cases
Frame shift: 15 cases
30
22 (12.7%)
Family history of
breast or first-degree
ovarian cancer
Bilateral breast
cancer
Male breast
cancer
Multiple organ
cancer
Earlier age of onset
(<35 yr)
Total
Cases tested 86 15 5 16 74 173*
BRCA1 mutation 13 (15.1%) 2 (13%) 1 (20%) 2 (13%) 5 (6.8%) 15 (8.7%)
BRCA2 mutation 6 (7%) 1 (6.7%) - - 1 (1%) 7 (4%)
Total (%) 19 (22.1%) 3 (20%) 1 (20%) 2 (13%) 6 (8.1%) 22 (12.7%)
*Of total 173 cases, 23 cases have two high-risk factors.
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cer (14).
At present, hundreds of BRCA mutations are known. Most
of these are nonsense or frame shift mutations, which can be
found throughout the entire gene sequence and produce trun-
cated proteins (15). Due to founder effects as well as other envi-
ronmental and geographical factors, the prevalence of BRCA
mutations is variable among different populations (10, 11).
In this report, we evaluated the prevalence of BRCA1 and
BRCA2 mutations in high-risk patients as well as in unselect-
ed breast cancer patients in Korea. We found that the preva-
lence of these mutations was about 4-5 times higher in high-
risk patients than in unselected patients. To our knowledge,
this is the first population-based report of BRCA mutations
in breast cancer patients in Korea. Interestingly, however, we
did not detect any of the three founder mutations identified in
individuals of Ashkenazi Jewish decent (185delAG and 5382
insC for BRCA1 and 6174delT for BRCA2) or the 999del5
mutation for BRCA2 common to the Icelandic population
(6) in any Korean patient.
We found that a family history of breast or first-degree ovar-
ian cancer was the most important high-risk factor for BRCA
mutation, followed by bilateral breast cancer and male breast
cancer. Each of these factors increased the likelihood of detect-
ing BRCA mutations 7- to 8-fold compared with the unselect-
ed patients. In contrast, earlier age at onset, prior to age 35,
increased the likelihood of BRCA mutations 3-fold compared
with the unselected patients. Our finding of BRCA mutations
in 23% of Korean patients with a family history of breast can-
cer is in good agreement with findings in Caucasian and other
Asian patients, in whom BRCA mutations were detected in
11% to 33% of those with a family history of breast cancer
(2, 19, 20, 24). In some of these studies, 45% to 51% of pa-
tients with two or more relatives with breast cancer were found
to have BRCA mutations (20, 24).
It has been reported that nine of 21 (43%) Korean families
containing two or more affected first- or second-degree rela-
tives with breast and/or ovarian cancer had BRCA germline
mutations (four frameshift and five nonsense) (9). In our study,
we detected 15 frameshift mutations and seven nonsense muta-
tions.
There are few reports on the prevalence of BRCA gene muta-
tions in unselected breast cancer patients in Asia. The preva-
lence of these mutations has been estimated at 5.1% to 6.7%,
with the phenotypes varying by ethnicity (2, 16). In our study
of unselected Korean breast cancer patients, however, we de-
tected a lower prevalence of BRCA mutations (2.8%), which
may be due to ethnic differences. It should be noted, however,
that the numbers of unselected Asian breast cancer patients
canvassed to date is low; larger numbers may give a more accu-
rate estimate of the frequency of BRCA mutations in Asia, as
well as of the variations between Asian populations.
The prevalence of BRCA mutations in patients with early-
onset breast cancer is quite different depending on ethnicity.
For example, this rate has been found to be 20-30% in Ashke-
nazi Jewish and Icelandic patients (7, 17, 18), less than 10%
in Caucasian patients (19-22), and 6-11% in Asian patients,
including our results (2, 23).
We found that the prevalence of BRCA mutations in pa-
tients with two or more risk factors was 2.7 times higher than
that in patients with a single risk factor. These risk factors
included early age at diagnosis, bilateral cancer, multiple organ
cancer, and male breast cancer, together with a family history
of breast or first-degree ovarian cancer. For example, 28.6%
of patients diagnosed prior to age 35 yr and who had a family
history of breast or first-degree ovarian cancer carried BRCA
mutations, a prevalence comparable to the 29.7% of non-
Ashkenazi breast cancer patients diagnosed before age 40 yr
who had one relative diagnosed with breast cancer before age
50 (24). In this latter report, 50.7% of these patients who had
two relatives diagnosed with breast cancer before age 50 car-
ried germline BRCA mutations (24).
We detected BRCA mutations in 50% of patients with
bilateral cancer, multiple organ cancer, or male breast cancer
and a familial history, and with bilateral cancer diagnosed
below age 35, although the number of patients in each cate-
gory was small. Larger, population-based studies are needed
to evaluate the impact of these combined risk factors on the
prevalence of BRCA mutations. Interestingly, it has been
reported that a family history of bilateral breast cancer did not
substantially increase the likelihood of BRCA mutations (19).
Previous investigations have suggested that male breast can-
cer may be another hallmark for the presence of BRCA2 muta-
tions (19, 25, 26). In contrast, of the small number (5) of male
breast cancer patients that we assayed, none had a BRCA2
mutation, and only one had a BRCA1 mutation.
BRCA1 mutations have been found to be significantly more
common in women with a family history of ovarian cancer
than in those with a family history of breast cancer (19). In
contrast, BRCA2 mutations were not found to be more com-
mon in women with a family history of ovarian cancer. In
Asian countries, BRCA mutations have been detected in
4.7% to 15.8% of patients with ovarian cancer (16, 27). While
the prevalence of BRCA mutations has been shown to be in-
creased in patients with earlier onset breast cancer, the preva-
lence of these mutations was no higher in women with ovar-
ian cancer diagnosed before age 50 than in those diagnosed
at a later age (24).
We believe that our data on the personal and family his-
tories of the individuals tested are accurate because the infor-
mation was obtained from the test requisition form by a re-
search fellow. Moreover, the F-CSGE technique we used has
been found to detect 98% of BRCA mutations, a sensitivity
at least equal to that of other gel-based genomic screening
techniques (28).
Generally, tests for BRCA mutations are recommended in
cases with 10% or higher prevalence rate of the mutation in
a clinical setting. Our study data suggest that breast cancer
patients with high-risk factors, including a family history ofbreast or first-degree ovarian cancer, bilateral cancer, male
breast cancer, multiple organ cancer, and earlier age at onset,
who have a higher prevalence of BRCA mutations, should be
tested for BRCA mutations. Our finding, that the phenotype
of BRCA mutations in Korea is different from those of Ashke-
nazi Jew and other populations, suggests the need for large-
scale, population-based studies to establish the clinicopatho-
logic characteristics as well as the genetic pathology related
to BRCA mutations in Korean breast cancer patients.
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